Citations

Showing 10 of 108119 citations.

Development of the AI-Cirrhosis-ECG Score: An Electrocardiogram-Based Deep Learning Model in Cirrhosis
Ahn, Joseph , Buryska, Seth , Kamath, Patrick S. , Friedman, Paul A. , Shah, Vijay H. , Simonetto, Douglas A. , Ahn, Joseph C , Rattan, Puru , Simonetto, Douglas A , Attia, Zachi I. , Mullan, Aidan F. , Allen, Alina M. , Noseworthy, Peter A.

Mayo Clinic

American Journal of Gastroenterology | January 14, 2022 | Volume: 117 | Issue: 3 | Pages: 424-432

10.14309/ajg.0000000000001617 | PMID 35029163 Get It

INTRODUCTION: Cirrhosis is associated with cardiac dysfunction and distinct electrocardiogram (ECG) abnormalities. This study aimed to develop a proof-of-concept deep learning-based artificial intelligence (AI) model that could detect cirrhosis-related signals on ECG and generate an AI-Cirrhosis-ECG (ACE) score that would correlate with disease severity. METHODS: A review of Mayo Clinic's electronic health records identified 5,212 patients with advanced cirrhosis ≥18 years who underwent liver transplantation at the 3 Mayo Clinic transplant centers between 1988 and 2019. The patients were matched by age and sex in a 1:4 ratio to controls without liver disease and then divided into training, validation, and test sets using a 70%-10%-20% split. The primary outcome was the performance of the model in distinguishing patients with cirrhosis from controls using their ECGs. In addition, the association between the ACE score and the severity of patients' liver disease was assessed. RESULTS: The model's area under the curve in the test set was 0.908 with 84.9% sensitivity and 83.2% specificity, and this performance remained consistent after additional matching for medical comorbidities. Significant elevations in the ACE scores were seen with increasing model for end-stage liver disease-sodium score. Longitudinal trends in the ACE scores before and after liver transplantation mirrored the progression and resolution of liver disease. DISCUSSION: The ACE score, a deep learning model, can accurately discriminate ECGs from patients with and without cirrhosis. This novel relationship between AI-enabled ECG analysis and cirrhosis holds promise as the basis for future low-cost tools and applications in the care of patients with liver disease.
Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases
Weaver, Kimberly N. , Zhang, Xian , Dai, Xiangfeng , Watkins, Runa , Adler, Jeremy, Dubinsky, Marla C. , Kastl, Arthur , Bousvaros, Athos, Strople, Jenifer A., Higgins, Peter , Bewtra, Meenakshi , Bellaguarda, Emanuelle, Boccieri, Margie , Firestine, Ann M. , Chun, Kelly , Fernando, Manory, Bastidas, Monique, Zikry, Michael, Long, Millie D. , Kappelman, Michael D. , Adler, Jeremy, Cross, Raymond K. , Ungaro, Ryan C. , Farraye, Francis A. , Bastidas, Monique, Adler, J

Mayo Clinic

American Journal of Gastroenterology | January 14, 2022 | Volume: 117 | Issue: 3 | Pages: 462-469

10.14309/ajg.0000000000001619 | PMID 35029167 Get It

INTRODUCTION: Although an additional coronavirus disease 2019 vaccine dose for immunocompromised persons has been recommended in some countries, further data to guide vaccination strategies for patients with inflammatory bowel disease (IBD) are urgently needed. We sought to identify factors affecting initial humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines among patients with IBD. METHODS: In this prospective cohort of SARS-CoV-2 immunized patients with IBD, we evaluated associations between participant age, sex, vaccine type, medication use, and the presence of a detectable antireceptor binding domain antibody and quantitative antibody level. RESULTS: In total, 1,909 participants were included (1,123, 692, and 94 received BNT162b2, mRNA-1273, and Ad26.COV2.S, respectively) of whom 96% achieved a positive antibody response. On multivariable analysis, factors associated with lack of antibody response were older age ( P = 0.043), BNT162b2 vs mRNA-1273 (odds ratio [OR] 2.1, 95% confidence interval [CI] 1.0–3.9), and combination therapy with anti-TNF and 6MP, azathioprine, or methotrexate (OR 4.2, 95% CI 2.4–7.3). The use of 5-aminosalicylate or sulfasalazine (OR 0.3, 95% CI 0.1–0.8) and ustekinumab (OR 0.2, 95% CI 0.05–0.8) was associated with decreased odds of lacking antibody response. DISCUSSION: Most patients with IBD mount an initial response to SARS-CoV-2 vaccination; however, older patients and those treated with anti-TNF and immunomodulator have blunted responses and may benefit the most from an additional vaccine dose. Patients treated with other classes of immunosuppressive medications have more robust initial immune responses to vaccination. These data should inform key decisions about patient selection for additional coronavirus disease 2019 vaccine doses in patients with IBD.
Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer: A Systematic Review
Dora, Chandler , Clarke, Gina M., Frey, Gregory, Sella, David, Dora, Chandler D , Clarke, Gina M., Frey, Gregory, Sella, David

Mayo Clinic

Journal of Endourology | January 14, 2022 | Volume: 36 | Issue: 6 | Pages: 841-854

10.1089/end.2021.0866 | PMID 35029127 Get It

Purpose: MRI-guided transurethral ultrasound ablation (TULSA) uses real-time MR thermometry feedback to target prostate disease. We systematically review the literature to synthesize efficacy, functional, and safety outcomes and assess the influence of planned ablation fraction on outcome. Materials and Methods: PubMed, Embase, and the Cochrane Library were searched from inception to June 2021 following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Studies reporting at least one efficacy, functional, or safety outcome after a single TULSA treatment were included. The relationship of freedom from salvage treatment and potency preservation with planned ablation volume was modeled. Results: Two hundred twenty-four patients were treated in 10 studies with up to a 5-year follow-up, mainly for primary localized prostate cancer (PCa) plus smaller cohorts with recurrent PCa, and locally advanced PCa (LAPC). The prostate-specific antigen decline from baseline up to 2 years, including focal to whole-gland ablation plans, was 54% to 97%. The rate of salvage treatment after one TULSA treatment for primary PCa was 7% to 17%. Continence and potency preservation were from 92% to 100% and from 75% to 98%. Urinary symptoms were stable in men with good voiding function at baseline, and 85% of men with concurrent PCa and lower urinary tract symptoms met the criteria for improvement. Symptom relief in a small cohort of men with LAPC was observed. Grade III adverse events were incurred by 13/224 men (6%), with no rectal injury/fistula or Grade IV complication. The planned ablation fraction was linearly related to salvage-free survival. The relationship between potency preservation and planned ablation fraction followed a sigmoid curve. Conclusions: As an alternative to conventional treatments, TULSA is safe and effective for prostate tissue ablation in men with primary PCa. There is also evidence that TULSA delivers effective relief of urinary symptoms while treating PCa in a single, low-morbidity procedure. The likelihood of freedom from additional treatment or potency preservation is associated with the planned ablation fraction.
Colonoscopy-Related Adverse Events in Patients With Abnormal Stool-Based Tests: A Systematic Review of Literature and Meta-analysis of Outcomes
Chandan, Saurabh , Yarra, Pradeep , Khan, Shahab R. , Ramai, Daryl , Kassab, Lena L., Chandan, Saurabh , Facciorusso, Antonio , Mohan, Babu P. , Bilal, Mohammad , Shaukat, Aasma

Mayo Clinic

American Journal of Gastroenterology | January 14, 2022 | Volume: 117 | Issue: 3 | Pages: 381-393

10.14309/ajg.0000000000001614 | PMID 35029161 Get It

INTRODUCTION: Colorectal cancer (CRC) screening programs based on the fecal immunochemical test (FIT) and guaiac-based fecal occult blood (gFOBT) are associated with a substantial reduction in CRC incidence and mortality. We conducted a systematic review and comprehensive meta-analysis to evaluate colonoscopy-related adverse events in individuals with a positive FIT or gFOBT. METHODS: A systematic and detailed search was run in January 2021, with the assistance of a medical librarian for studies reporting on colonoscopy-related adverse events as part of organized CRC screening programs. Meta-analysis was performed using the random-effects model, and the results were expressed for pooled proportions along with relevant 95% confidence intervals (CIs). RESULTS: A total of 771,730 colonoscopies were performed in patients undergoing CRC screening using either gFOBT or FIT across 31 studies. The overall pooled incidence of severe adverse events in the entire patient cohort was 0.42% (CI 0.20–0.64); I 2 = 38.76%. In patients with abnormal gFOBT, the incidence was 0.2% (CI 0.1–0.3); I 2 = 24.6%, and in patients with a positive FIT, it was 0.4% (CI 0.2–0.7); I 2 = 48.89%. The overall pooled incidence of perforation, bleeding, and death was 0.13% (CI 0.09–0.21); I 2 = 22.84%, 0.3% (CI 0.2–0.4); I 2 = 35.58%, and 0.01% (CI 0.00–0.01); I 2 = 33.21%, respectively. DISCUSSION: Our analysis shows that in colonoscopies performed after abnormal stool-based testing, the overall risk of severe adverse events, perforation, bleeding, and death is minimal.
Defining AMIA’s artificial intelligence principles
Solomonides, Anthony , Koski, Eileen , Atabaki, Shireen M., Weinberg, Scott S., McGreevey, John D. , Kannry, Joseph , Petersen, Carolyn , Lehmann, Christoph U. , Solomonides, Anthony E , Kannry, Joseph L , Lehmann, Christoph U , Petersen, Carolyn

Mayo Clinic

Journal of the American Medical Informatics Association | January 14, 2022 | Volume: 29 | Issue: 4 | Pages: 585-591

10.1093/jamia/ocac006 | PMID 35190824 Get It

Abstract Recent advances in the science and technology of artificial intelligence (AI) and growing numbers of deployed AI systems in healthcare and other services have called attention to the need for ethical principles and governance. We define and provide a rationale for principles that should guide the commission, creation, implementation, maintenance, and retirement of AI systems as a foundation for governance throughout the lifecycle. Some principles are derived from the familiar requirements of practice and research in medicine and healthcare: beneficence, nonmaleficence, autonomy, and justice come first. A set of principles follow from the creation and engineering of AI systems: explainability of the technology in plain terms; interpretability, that is, plausible reasoning for decisions; fairness and absence of bias; dependability, including “safe failure”; provision of an audit trail for decisions; and active management of the knowledge base to remain up to date and sensitive to any changes in the environment. In organizational terms, the principles require benevolence—aiming to do good through the use of AI; transparency, ensuring that all assumptions and potential conflicts of interest are declared; and accountability, including active oversight of AI systems and management of any risks that may arise. Particular attention is drawn to the case of vulnerable populations, where extreme care must be exercised. Finally, the principles emphasize the need for user education at all levels of engagement with AI and for continuing research into AI and its biomedical and healthcare applications.
Associations Between Glycemic Traits and Colorectal Cancer: A Mendelian Randomization Analysis
Murphy, Neil , Song, Mingyang , Papadimitriou, Nikos , Carreras‐Torres, Robert , Langenberg, Claudia , Martin, Richard M. , Tsilidis, Konstantinos K. , Barroso, Inês , Chen, Ji , Vincent, Emma E. , Cotterchio, Michelle , Gruber, Stephen B. , Pai, Rish K. , Perez‐Cornago, Aurora , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Vodička, Pavel , Wu, Anna H. , Peters, Ulrike , Gunter, Marc J. , Frayling, Timothy M , Bull, Caroline J , Vincent, Emma E , Gruber, Stephen B , Pai, R K , Perez-Cornago, Aurora , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Wolk, Alicja , Chan, Andrew T , Gunter, Marc J , Murphy, Neil , Martin, Richard M , Song, Mingyang , Carreras-Torres, Robert , Tsilidis, Konstantinos K , Papadimitriou, Nikos , Vodicka, Pavel , Bull, Caroline J. , Newcomb, Polly A. , Wolk, Alicja , Chan, Andrew T.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 14, 2022 | Volume: 114 | Issue: 5 | Pages: 740-752

10.1093/jnci/djac011 | PMID 35048991 Get It

Abstract Background Glycemic traits—such as hyperinsulinemia, hyperglycemia, and type 2 diabetes—have been associated with higher colorectal cancer risk in observational studies; however, causality of these associations is uncertain. We used Mendelian randomization (MR) to estimate the causal effects of fasting insulin, 2-hour glucose, fasting glucose, glycated hemoglobin (HbA1c), and type 2 diabetes with colorectal cancer. Methods Genome-wide association study summary data were used to identify genetic variants associated with circulating levels of fasting insulin (n = 34), 2-hour glucose (n = 13), fasting glucose (n = 70), HbA1c (n = 221), and type 2 diabetes (n = 268). Using 2-sample MR, we examined these variants in relation to colorectal cancer risk (48 214 case patient and 64 159 control patients). Results In inverse-variance models, higher fasting insulin levels increased colorectal cancer risk (odds ratio [OR] per 1-SD = 1.65, 95% confidence interval [CI] = 1.15 to 2.36). We found no evidence of any effect of 2-hour glucose (OR per 1-SD = 1.02, 95% CI = 0.86 to 1.21) or fasting glucose (OR per 1-SD = 1.04, 95% CI = 0.88 to 1.23) concentrations on colorectal cancer risk. Genetic liability to type 2 diabetes (OR per 1-unit increase in log odds = 1.04, 95% CI = 1.01 to 1.07) and higher HbA1c levels (OR per 1-SD = 1.09, 95% CI = 1.00 to 1.19) increased colorectal cancer risk, although these findings may have been biased by pleiotropy. Higher HbA1c concentrations increased rectal cancer risk in men (OR per 1-SD = 1.21, 95% CI = 1.05 to 1.40), but not in women. Conclusions Our results support a causal effect of higher fasting insulin, but not glucose traits or type 2 diabetes, on increased colorectal cancer risk. This suggests that pharmacological or lifestyle interventions that lower circulating insulin levels may be beneficial in preventing colorectal tumorigenesis.
Association of meningitis and clival canal defect: case illustration, management, and systematic review of the literature
Thorwarth, Ryan, Bhuskute, Aditi, Gnagi, Sharon H. , Thorwarth, Ryan M, Singh, Rohin , Bendok, Bernard R. , Rath, Tanya J. , Lal, Devyani

Mayo Clinic

Journal of Neurosurgery: Pediatrics | January 14, 2022 | Volume: 29 | Issue: 4 | Pages: 379-386

10.3171/2021.11.peds21388 | PMID 35171832 Get It

OBJECTIVE Improper embryological development of the clivus, a bony structure that comprises part of the skull base, can lead to a clival canal defect. Previously thought to be a benign condition, clival canals have been reported to be associated with meningitis and meningoceles. In this review, the authors sought to present an unpublished case of a patient with a clival canal defect associated with meningitis and to evaluate all other reported cases. METHODS In October 2020, a search of PubMed, Web of Science, and Scopus was conducted to identify all cases of clival canals reported from January 1, 1980, through October 31, 2020. RESULTS Including the case presented herein, 13 cases of clival canals, 11 in children (84.6%) and 2 in adults (15.4%), have been identified. Of the pediatric patients, 5 (45.5%) had an associated meningocele, and 8 (72.7%) had meningitis. Nine of the 13 patients (69.2%) had defects that were treated surgically, 5 (38.5%) by a transnasal approach and 4 (30.8%) by a transoral approach. Two patients (15.4%) were treated with drainage and antibiotics, 1 patient (7.7%) was treated solely with antibiotics, and 1 patient (7.7%) was not treated. In the literature review, 8 reports of clival canals were found to be associated with meningitis, further contributing to the notion that the clival canal may be an overlooked source of recurrent infection. In several of these cases, surgical repair of the lesion was curative, thus preventing continued episodes of meningitis. CONCLUSIONS When a patient has recurrent meningitis with no clear cause, taking a closer look at clival anatomy is recommended. In addition, if a clival canal defect has been identified, surgical repair should be considered a safe and effective primary treatment option.
Diffuse Lewy body disease presenting as Parkinson's disease with progressive aphasia
Koga, Shunsuke , Murakami, Aya , Josephs, Keith A. , Dickson, Dennis W. , Koga, Shunsuke , Dickson, Dennis W

Mayo Clinic

Neuropathology | January 14, 2022 | Volume: 42 | Issue: 1 | Pages: 82-89

10.1111/neup.12780 | PMID 35029300 Get It

Primary progressive aphasia (PPA) is a progressive language disorder often due to an underlying neurodegenerative disease. The most common pathologies associated with PPA include frontotemporal lobar degeneration (FTLD)‐tau, FTLD‐associated with transactivation response DNA‐binding protein of 43 kDa (TDP‐43) (FTLD‐TDP), and Alzheimer's disease (AD). Accumulating evidence has suggested that Lewy body disease (LBD) can also be associated with PPA. We herein report a 78‐year‐old Caucasian woman who initially presented with levodopa‐responsive parkinsonism at age 67 and later developed cognitive impairment, visual hallucinations, rapid eye movement sleep behavior disorder, and progressive aphasia, characterized by reduced spontaneous speech, word‐finding difficulty, and difficulties in writing and reading. 18Fluorodeoxyglucoase (FDG)‐positron emission tomography (PET) performed at the age of 73 years identified hypometabolism in the frontal (right > left), temporal (left > right), and parietal (left > right) lobes. Neuropathological assessment revealed diffuse LBD (DLBD), AD, and TDP‐43 stage 6 with prehippocampal sclerosis. Senile plaques were numerous, but only a few neurofibrillary tangles were present in the neocortex. The Braak neurofibrillary tangle stage was IV, and the Thal amyloid phase was 3. Lewy‐related pathology was severe in the neocortex, as well as limbic cortices, basal forebrain, amygdala, and brainstem. Compared to 166 DLBD cases with a clinical diagnosis of dementia with Lewy bodies (DLB), the Lewy body count of the patient in this report was highest in the inferior parietal cortex, followed by midfrontal and superior temporal cortices. The findings suggest that severe cortical LBD pathology has contributed to her progressive aphasia. Autopsy cases of LBD presenting as PPA have been reported, but patients with PD and autopsy‐proven DLBD who later developed progressive aphasia have not been reported. Our findings indicate that PD can be associated with progressive aphasia later in the disease course. Although uncommon, LBD should be considered as a differential diagnosis of progressive aphasia.
Human neural cell type‐specific extracellular vesicle proteome defines disease‐related molecules associated with activated astrocytes in Alzheimer's disease brain
You, Yang , Muraoka, Satoshi , Jedrychowski, Mark P., Hu, Jianqiao, McQuade, Amanda , Aslebagh, Roshanak, Gygi, Steven P. , Blurton‐Jones, Mathew , Poon, Wayne W. , Ikezu, Tsuneya , Ikezu, Tsuneya , Yang, You , Young‐Pearse, Tracy L. , Shaffer, Scott A.

Mayo Clinic

Journal of Extracellular Vesicles | January 13, 2022 | Volume: 11 | Issue: 1 | Pages: No page available

10.1002/jev2.12183 | PMID 35029059 Get It

Abstract In neurodegenerative diseases, extracellular vesicles (EVs) transfer pathogenic molecules and are consequently involved in disease progression. We have investigated the proteomic profiles of EVs that were isolated from four different human‐induced pluripotent stem cell‐derived neural cell types (excitatory neurons, astrocytes, microglia‐like cells, and oligodendrocyte‐like cells). Novel cell type‐specific EV protein markers were then identified for the excitatory neurons (ATP1A3, NCAM1), astrocytes (LRP1, ITGA6), microglia‐like cells (ITGAM, LCP1), and oligodendrocyte‐like cells (LAMP2, FTH1), as well as 16 pan‐EV marker candidates, including integrins and annexins. To further demonstrate how cell‐type‐specific EVs may be involved in Alzheimer's disease (AD), we performed protein co‐expression network analysis and conducted cell type assessments for the proteomes of brain‐derived EVs from the control, mild cognitive impairment, and AD cases. A protein module enriched in astrocyte‐specific EV markers was most significantly associated with the AD pathology and cognitive impairment, suggesting an important role in AD progression. The hub protein from this module, integrin‐β1 (ITGB1), was found to be significantly elevated in astrocyte‐specific EVs enriched from the total brain‐derived AD EVs and associated with the brain β‐amyloid and tau load in independent cohorts. Thus, our study provides a featured framework and rich resource for the future analyses of EV functions in neurodegenerative diseases in a cell type‐specific manner.
The digital transformation of hepatology: The patient is logged in
Wu, Tiffany , Simonetto, Douglas A. , Shah, Vijay H. , Halamka, John D, Shah, Vijay H , Simonetto, Douglas A , Wu, Tiffany , Halamka, John

Mayo Clinic

Hepatology | January 13, 2022 | Volume: 75 | Issue: 3 | Pages: 724-739

10.1002/hep.32329 | PMID 35028960 Get It

Abstract The rise in innovative digital health technologies has led a paradigm shift in health care toward personalized, patient‐centric medicine that is reaching beyond traditional brick‐and‐mortar facilities into patients’ homes and everyday lives. Digital solutions can monitor and detect early changes in physiological data, predict disease progression and health‐related outcomes based on individual risk factors, and manage disease intervention with a range of accessible telemedicine and mobile health options. In this review, we discuss the unique transformation underway in the care of patients with liver disease, specifically examining the digital transformation of diagnostics, prediction and clinical decision‐making, and management. Additionally, we discuss the general considerations needed to confirm validity and oversight of new technologies, usability and acceptability of digital solutions, and equity and inclusivity of vulnerable populations.